文献速递主动脉疾病

肾功能对开窗分支腔内修复胸腹及肾旁主动脉瘤后生存的影响

Effect of renal function on patient survival after endovascular thoracoabdominal and pararenal aortic aneurysm repair.
PubMed 文献 · J Vasc Surg · 2020-12-16

本研究基于单中心前瞻性非随机队列(2013-2017年,231例)分析开窗分支腔内修复(FB-EVAR)胸腹主动脉瘤(TAAA)和肾旁主动脉瘤(PRAA)后肾功能与生存的关系。按术前慢性肾脏病(CKD)分期分组,CKD 4-5期(9例,基线肌酐均>2.0 mg/dL)与CKD 1-3期相比,30天死亡率(0% vs 0.5%,P=.73)及1年、3年生存率(95% vs 88%;84% vs 75%,log-rank P=.98)均无显著差异。结论提示经选择的CKD 4-5期患者行FB-EVAR可能获得与肾功能正常至中度损害者相似的短长期生存。

要点

  • CKD 4-5期患者(基线肌酐>2.0 mg/dL)行FB-EVAR后30天死亡率为0%。
  • CKD 1-3期与4-5期患者1年及3年生存率无显著差异(P=.98)。
  • 肾功能不全对开放手术是禁忌,但对经选择的FB-EVAR患者可能并非如此。

核心结论

  • 经选择的CKD 4-5期患者行FB-EVAR后短期和长期死亡率与肾功能正常至中度损害者相似。

研究设计与样本

  • 单中心前瞻性非随机研究,纳入2013-2017年连续接受FB-EVAR的PRAA和TAAA患者231例,随访1年。
  • 按术前CKD分期分组:CKD 1-2期126例,CKD 3期96例,CKD 4-5期9例(基线肌酐均>2.0 mg/dL)。
  • 平均年龄74.6±6.7岁,男性占71%;中位随访2.6年(四分位距1.5-3.7年)。

主要发现

  • CKD 4-5期患者动脉瘤稍大(6.5 vs 7 cm;P=.15),人口学资料与肾功能正常者相似。
  • 30天死亡率:CKD 1-3期为0.5%(n=1),CKD 4-5期为0%(P=.73)。
  • 1年和3年生存率:CKD 1-3期分别为95%和88%,CKD 4-5期分别为84%和75%(log-rank P=.98)。
  • 随访期间CKD 4-5期组有2例死亡。

临床怎么用

  • 对于经选择的CKD 4-5期复杂主动脉瘤患者,FB-EVAR可作为开放手术禁忌时的替代选择。
  • 术前应依据CKD分期评估风险,但肾功能不全不应单独作为FB-EVAR的绝对禁忌。

局限性

  • CKD 4-5期样本量小(9例),统计效能有限。
  • 单中心前瞻性非随机研究设计,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal dysfunction can be a prohibitive risk for open repair of complex thoracoabdominal aortic aneurysms (TAAAs) and pararenal aortic aneurysms (PRAAs). However, the effect of renal dysfunction from fenestrated and branched endovascular aneurysm repair (FB-EVAR) on outcomes is poorly defined. Our objective was to review the association of renal function on patient survival after FB-EVAR. METHODS: The present study reviewed the clinical data of consecutive patients enrolled in a prospective nonrandomized study to investigate FB-EVAR for PRAAs and TAAAs at a single institution with 1 year of follow-up (2013-2017). The patients were categorized by preoperative chronic kidney disease (CKD) classification, and the early- and long-term mortality was assessed. RESULTS: During the study period, 231 patients had undergone FB-EVAR for 80 PRAAs, 89 type I-III TAAAs, and 62 type IV TAAAs. The mean age was 74.6 ± 6.7 years, and 71% were men. Of the 231 patients, 126 had had CKD stage 1-2, 96 CKD stage 3, and 9 CKD stage 4-5 (all with baseline creatinine >2.0 mg/dL). Patients with CKD stage 4-5 had demographic data similar to those with normal renal function but had had slightly larger aneurysms (6.5 vs 7 cm; P = .15). The 30-day mortality was 0.5% (n = 1) for those with CKD 1-3 vs 0% for those with CKD 4-5 (P = .73). The 1- and 3-year survival analysis showed no major hazards (95% vs 88% and 84% vs 75%, respectively; log-rank P = .98) between the CKD 1-3 and CKD 4-5 groups. The median follow-up period was 2.6 years (interquartile range, 1.5-3.7 years). Two patients with CKD 4-5 had died during the follow-up period. CONCLUSIONS: Although a small sample size for evaluation, selected patients with CKD 4-5 might have similar short- and long-term mortality compared with those with normal to moderate renal dysfunction after FB-EVAR. Although a major contraindication for open repair, renal dysfunction might not be as prohibitive for endovascular repair in well-selected patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cajas-Monson L, D'Oria M, Tenorio E, et al. Effect of renal function on patient survival after endovascular thoracoabdominal and pararenal aortic aneurysm repair. J Vasc Surg. 2020. PMID: 33340697. doi:10.1016/j.jvs.2020.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。